• Quest Diagnostics Incorporated recently integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumors into Flatiron Health’s OncoEMR via a pilot with American Oncology Network and other community providers, giving 4,700 clinicians at 1,600 U.S. cancer care locations easier access to these tests within their existing electronic health record workflows.
• This move makes Quest the largest clinical reference lab to plug advanced oncology testing directly into OncoEMR’s Molecular Profiling Integration feature, highlighting how specialized IT and EHR connectivity are becoming core to expanding use of complex molecular diagnostics in community oncology practices.
• We’ll now examine how embedding Haystack MRD and genomic profiling into OncoEMR workflows could reinforce Quest Diagnostics’ advanced diagnostics investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you need to believe its push into advanced, data driven testing can offset reimbursement pressure and industry price competition. The OncoEMR integration looks directionally helpful to the near term advanced diagnostics catalyst, but not material enough on its own to change the biggest current risk around potential PAMA related reimbursement headwinds.

The most relevant recent announcement here is Quest’s Haystack MRD test gaining New York State approval, completing U.S. wide authorization. Together with the OncoEMR rollout, this expands both where Haystack can be used and how easily oncologists can order it, tying directly into the narrative that higher value oncology and preventive testing could support test mix and margins over time.

Yet investors should be aware that if PAMA cuts proceed as currently framed, Quest could still face roughly US$100 million of annual pricing pressure...

Quest Diagnostics’ narrative projects $13.0 billion revenue and $1.4 billion earnings by 2029.

Uncover how Quest Diagnostics' forecasts yield a $223.44 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Two members of the Simply Wall St Community currently see fair value for Quest between about US$223 and US$328 per share, a wide span for the same business. Set against that, the key question many are weighing is whether higher margin advanced and preventive testing can sufficiently blunt ongoing reimbursement and pricing risks over time, so it is worth considering several viewpoints before deciding how that trade off could affect Quest’s performance.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth just $223.44!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

No Opportunity In Quest Diagnostics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.